# Intensified Post Remission Therapy Containing PEG-Asparaginase

> **NCT00184041** · PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 47 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine

## Key facts

- **NCT ID:** NCT00184041
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2011-12
- **Final completion:** 2012-12
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2014-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00184041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00184041, "Intensified Post Remission Therapy Containing PEG-Asparaginase". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00184041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*